Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs GraniteShares 2x Long COIN Daily ETF (CONL) Price & Performance

Amgen, Inc.Trade
GraniteShares 2x Long COIN Daily ETFTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs GraniteShares 2x Long COIN Daily ETF — how do they compare? Amgen, Inc. trades at $416.54 (market cap $224.14B), while GraniteShares 2x Long COIN Daily ETF trades at $4.12. The key difference: Amgen, Inc. pays a 2.43% dividend while GraniteShares 2x Long COIN Daily ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals.

AMGNCONL
Market Cap
$224.14B
Sector
HealthLeveraged / Inverse
52-Week High
$417.20$48.70
52-Week Low
$271.18$3.93
Enterprise Value
$267.45B
Dividend Yield
2.43%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.

Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.

GraniteShares 2x Long COIN Daily ETF

CONL (GraniteShares 2x Long COIN Daily ETF) trades at $4.065, down 0.61% on the day, with a bearish technical outlook as moving averages and key indicators signal selling pressure. The ETF has experienced significant volatility, losing 67% year-to-date according to 24/7 Wall Street (2026-06-06), reflecting the inherent risks of daily-reset leveraged strategies. Recent news highlights the challenges of timing leveraged ETF investments, with investors missing substantial returns due to poor trading timing.

The outlook remains challenging given the ETF's structure amplifies daily Coinbase volatility. While cryptocurrency trends may offer occasional upside, the daily reset mechanism creates compounding risks that have eroded value significantly. Investors should understand this is a tactical trading instrument, not a long-term investment vehicle, with high risk of capital erosion during volatile periods.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About GraniteShares 2x Long COIN Daily ETF

CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.

Read more on CONL